I'm a 67-year-old runner — these are the 6 best men's running shoes in 2025
After years of playing soccer, squash and distance running on hard surfaces, I needed both my knees scoped (surgery to repair torn cartilage). Initially, my doctor recommended I stop running altogether. But after extensive badgering, he eventually gave me the green light to give running another shot, providing I took careful steps — literally. Steps as in: ramping up slowly (not unlike when I first began running as a late starter at 39), not running too hard or for too long, and importantly: choosing the right shoes. All of which has made it possible for me to keep running today as a 67-year-old. And why not? As studies conclusively show, running helps keep seniors young. Whether you're in your 30s, your 50s, your 60s or beyond, these shoes will help you to put your best foot forward.
Best shoes for new runners
One of the key differences between walking and running is that with running, you're hitting the ground with twice as much force. Experts estimate the force of walking is 1.5 times your body weight, while running can be 2-3 times. Thus, choosing shoes that provide enough support is a key consideration.
Other good reads:
Best running shoes for men in 2025, according to a competitive distance runner
Best hiking shoes, clothes and accessories for men in 2025, according to an avid hiker
Best men's running shoes for racing and marathons in 2025, according to a competitive athlete
Best for runners returning from injury
After almost 30 years of running, I've experienced pretty much every kind of injury you can think of. So I know first-hand how important it is when you start back up to find a balance between choosing shoes that provide adequate support, but are light and responsive enough to be a "go-to shoe" when you are ready to pick up the pace.
Best trail shoes for running and hiking
Running or walking on trails, especially hilly ones, is a great way to ramp up your cardio without stressing your body as much as running faster does. They can often provide a softer surface to run on, too. That said, I've been on many trails where you have to navigate stones, rocks and tree roots, so having shoes with good grip and protection should be top of mind.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool
Yahoo
4 hours ago
- Yahoo
Trump's Foreign Aid Cuts Are Ruining Ethiopia's Progress on Maternal Mortality
And enabling the country's anti-abortion movement. Since January, Donald Trump has–surprise!–inflicted an innumerable amount of devastation on reproductive rights and maternal health. If you're a regular Jezebel reader, you know this is nothing new. But a new report by the Independent reveals the wickedness isn't just barbaric–it's global. The article focuses on Ethiopia, how it once 'won the battle against its maternal deaths crisis,' and well, how Trump's foreign aid cuts might just ruin the progress. In 2005, the country repealed its draconian abortion ban, which only permitted the procedure to save the mother's life or her health (sound familiar?). In the two decades since, abortion has been legal in cases of rape, incest, fetal abnormalities, among other exceptions. The progress thereafter was significant. A paper published in May 2024 revealed that during the first 20 years of the 21st century, the country had slashed its maternal death rate by 72% and neonatal death rate by 44%—an impressive feat compared to other governments in sub-Saharan Africa. Most Popular George Clooney Sounds Like a Lovely House Husband Ohio Woman Faces 'Abuse of a Corpse' Charge for Miscarriage in Another Post-Roe Nightmare Abortion Access Will, Once Again, Be Decided by the Supreme Court But between canceling 83% of USAID programs in March and slashing away billions of aid through the One Big Beautiful (I-am-so-sick-and-tired-of-this) Bill, legislators have essentially deserted aid organizations around the world and left thousands to cope without life-saving treatments. For Ethiopia, one of the largest beneficiaries of U.S. aid dollars, it has also meant shutting down healthcare providers. Funding cuts have 'significantly affected accessibility of services including family planning, maternal health services, even newborn, child health, adolescent, and youth health services,' Dr. Hailemariam Segni, the president of the Ethiopian Society of Obstetrics and Gynecology, explained to the outlet. Still, he predicts that 'the number of pregnancies will increase'—and with it, so will the complications. The Independent writes: With the dust settling after Trump ordered all foreign aid work to stop in January of this year, Ethiopia has come out as one of the biggest losers in the cuts. By March, the country had seen the second biggest cut by dollar amount, tied with the Democratic Republic of Congo and exceeded only by funding cuts to Ukraine, according to the Center for Global Development. Dr Shibru says 85 per cent of NGOs, crucial in the delivery of many of the country's health services, had stopped work or were shuttered. A quick refresher that foreign aid cuts aren't just sadistic and cruel, they're unnecessary. It's not about 'fiscal conservatism': the federal government spends just a paltry 1% of its budget on foreign aid—a literal drip in the bucket. It's not 'America First': it's a huge erosion of U.S. influence and a huge shake-up to the very institutions it set up in the first place (not that any said institutions are perfect–but that's a fight for another time). And any reproductive health or family planning organization abroad that so much as whispers the word 'abortion' gets its funding slashed by Trump's global gag rule. So much for the party of 'family values. Unfortunately, funding cuts are just the tip of the iceberg. Conceringly, there's a growing 'resurgent anti-rights movement' that wants to roll back the country's 2005 law–and with it, access to safe abortion. Because of this, fewer Ethiopians are accessing abortions through public facilities, according to data collected by the country's Ministry of Health, That's right, anti-abortionists in America are enabling a global ripple effect. And because aid cuts are creating a vacuum, another doctor explains, anti-abortion groups are getting new energy—and the opportunity—to step in. Even if Ethiopia manages to stave off its anti-abortionists, none of the cuts bode well for a country whose maternal mortality rate was steadily decreasing up until now. So well done, America. You've not just managed to up your own maternal death crisis–but you've sabotaged others', too. Yay. Like what you just read? You've got great taste. Subscribe to Jezebel, and for $5 a month or $50 a year, you'll get access to a bunch of subscriber benefits, including getting to read the next article (and all the ones after that) ad-free. Plus, you'll be supporting independent journalism—which, can you even imagine not supporting independent journalism in times like these? Yikes.
Yahoo
4 hours ago
- Yahoo
It's been a long road, but Blood Oxygen tracking is back for the newest Apple Watches in the US – but the feature isn't the same
When you buy through links on our articles, Future and its syndication partners may earn a commission. Following an 18-month ban, Blood Oxygen tracking is coming back to the Apple Watch Series 9, Series 10, and Ultra 2 It's not an entirely on-device experience anymore, though The Apple Watch still measures Blood Oxygen, but the iPhone will calculate and display the final result It's been a long 18 months, but Apple's announced that Blood Oxygen tracking and monitoring are returning to the Apple Watch Series 9, Series 10, and Ultra 2 in the United States. The feature was disabled and effectively banned on the Series 9 and Ultra 2 – then the Series 10, which launched later – after a ruling in January 2024 due to a patent dispute over the technology being used between Massimo and Apple. Now, thanks to iOS 18.6.1 and watchOS 11.6.1, which will roll out later today, the feature is returning in a 'redesigned' form. In its new iteration, the Apple Watch Series 9, Series 10, and Ultra 2's sensors can take a reading, then transmit the data to the connected iPhone, where it will be calculated and displayed in the Health app under 'Respiratory' readings. So no, you won't be able to take the reading, watch as it progresses, and then view the results right on your wrist, as you could before. Still, this does effectively return the tracking and monitoring functionality to the impacted Apple Watch models in the United States. In a statement shared, Apple explains the changes as: 'Users with these models in the U.S. who currently do not have the Blood Oxygen feature will have access to the redesigned Blood Oxygen feature by updating their paired iPhone to iOS 18.6.1, and their Apple Watch to watchOS 11.6.1. Following this update, sensor data from the Blood Oxygen app on Apple Watch will be measured and calculated on the paired iPhone, and results can be viewed in the Respiratory section of the Health app. This update was enabled by a recent U.S. Customs ruling.' The U.S. Customs ruling is key here, as this will return the feature to the Apple Watches sold when the ban began and was subsequently enforced. If you still have an older Apple Watch, or one sold prior to January 2024, the Blood Oxygen functionality remains unimpacted and won't be changed. That also goes for any models sold outside of the United States, which have been unimpacted by this ruling. Still, this does return the Blood Oxygen feature to the Apple Watch, even if it splits the experience between watch and phone. But this separation is likely key to having this allowed and approved by U.S. Customs. For those who have purchased an Apple Watch Series 9, 10, or Ultra 2 in those many months, this is a return to form and rounding out of the health tracking features on Apple's star wearable in the United States. Even in our Apple Watch Series 10 review, we noted that the Blood Oxygen tracking feature was missing in the US. Apple has a pretty smart rollout here, and considering rumors of further pushes into health features that we might see with future generations of Apple Watch models, it might be helpful to have these readings going straight into the Health app. Either route, though, if you've been waiting for Blood Oxygen tracking to return, it's back, but you'll want to make sure your iPhone is nearby if you want to see the results. While Apple has not shared an exact timing for the rollouts of iOS 18.6.1 and watchOS 11.6.1, it has promised to arrive today – August 14, 2025 – in the United States, and we'll update this piece when we see it rolling out. You might also like Constantly dismissing notifications on your Apple Watch? You're going to love Apple's watchOS 26 latest gesture I'm a fitness tracker expert, and here are my top 3 subscription-free picks for 2025 Garmin Venu X1 review: The most innovative Garmin watch in years, and a genuine Apple Watch Ultra rival
